Attention deficit hyperactivity disorder

Brain Canada launches Season 3 of Playing with Marbles podcast – inside youth mental health

Retrieved on: 
Monday, February 26, 2024
Anxiety, Mental health, Dissociative identity disorder, Borderline personality disorder, Marble (toy), Attention deficit hyperactivity disorder, Eating disorder, ADHD, OCD, Travel, Depression, Nursing

MONTREAL, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Playing with Marbles, Brain Canada’s English-language podcast on everything brain, is back.

Key Points: 
  • MONTREAL, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Playing with Marbles, Brain Canada’s English-language podcast on everything brain, is back.
  • This season we’re zeroing in on the perspectives of people with lived experience of different mental health conditions.
  • Half of Canadians will have experienced a mental illness by the age of 40, and young people are especially vulnerable to mental illness.
  • “One in four young people need to access mental health services every year,” says Dr. Viviane Poupon, President and CEO of Brain Canada.

Study: Prenatal COVID exposure associated with changes in newborn brain

Retrieved on: 
Thursday, February 22, 2024
Cortex, Paper, Oxygen, Anxiety, Nursing, Infection, Coronavirus, Magnetic resonance imaging, Inflammation, Neuron, Fetus, Schizophrenia, Hospital, Pregnancy, Learning, Life, Radiation, Risk, Human, COVID-19, Frontal lobe, Walking, Virus, Health, Mother, COVID, Infant, Patient, Depression, Attention deficit hyperactivity disorder, News, Child, Fungal infection, Spectrum, Placenta, Research, MRI, Brain, Medical imaging

The findings suggest that exposure to the coronavirus and being pregnant during the pandemic could play a role in shaping infant brain development, said Nickie Andescavage, M.D.

Key Points: 
  • The findings suggest that exposure to the coronavirus and being pregnant during the pandemic could play a role in shaping infant brain development, said Nickie Andescavage, M.D.
  • In contrast, an inner area of the brain, known as deep gray matter, was smaller than in unexposed babies.
  • “Their brains formed differently if they were exposed to COVID,” said Dr. Andescavage, adding that “those exposed to COVID had unique signatures” in the brain.
  • But other studies have linked maternal stress and depression to changes in the newborn brain .

Organization in Saguenay creating inclusive skills training for Canadians living with ADHD

Retrieved on: 
Friday, March 1, 2024
Skill, Disability, Woman, Social change, Emotion, Person, Indigenous peoples, Workplace, Attention deficit hyperactivity disorder, Investment, Work, Growth, Languages of Ethiopia, Problem solving, Language, Parent, Government, Success, Learning, Life, Communication, Gross domestic product, Literacy, GDP, Saguenay, Memory, Creativity, Employment, ADHD, Social, Workforce, Nursing

That is why the Government is investing in projects that will help Canadians improve their foundational and transferable skills.

Key Points: 
  • That is why the Government is investing in projects that will help Canadians improve their foundational and transferable skills.
  • The Government of Canada's Skills for Success Program focuses on nine main skills that Canadians need to participate, adapt and thrive in learning, work and life.
  • "Investing in innovating and caring associations, such as PANDA, is key to creating accessible and innovative training opportunities for all Canadians.
  • With the Bambooza training platform, funded through Employment and Social Development's Skills for Success program, we're helping Canadians with ADHD develop the best strategies for the workplace."

ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)

Retrieved on: 
Monday, February 12, 2024
Ophthalmology, Polygala, NET, EOP, FDA, Attention deficit hyperactivity disorder, Patent, Treatment, Phase II, Norepinephrine transporter, Neurology, Norepinephrine, European, CNS, Major depressive disorder, Map, ADHD, MDD, Pharmaceutical industry

2021314052, for the use of PDC-1421, a Radix Polygala (Polygala tenuifolia Willd) extract, used in the Company's asset ABV-1504 for the treatment of Major Depressive Disorder (MDD).

Key Points: 
  • 2021314052, for the use of PDC-1421, a Radix Polygala (Polygala tenuifolia Willd) extract, used in the Company's asset ABV-1504 for the treatment of Major Depressive Disorder (MDD).
  • The Company was previously awarded a U.S. patent, US 11,554,154 B2, on April 25, 2023, for the same treatment.
  • The patent application was submitted to the Australian Patent and Trademark Office under "Polygala Extract for the Treatment of Major Depressive Disorder."
  • The invention relates to oral administration of the formulation containing a Radix Polygala (Polygala tenuifolia Willd) extract, PDC-1421, as a capsule for treating Major Depressive Disorder.

Tris Pharma Appoints Michael Magee as Vice President, Quality & Compliance

Retrieved on: 
Wednesday, February 7, 2024
Science, Neurology, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Clinical Trials, Ketan, University of the Sciences, Windtree Therapeutics, Pharma, Growth, Knowledge, Attention deficit hyperactivity disorder, CGMP, Good manufacturing practice, Therapy, Patient, Pain, SCA, Ferring Pharmaceuticals, ADHD, DSM-IV codes, Drug development, Addiction, Johnson & Johnson

Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction and neurological disorders, today announced the appointment of Michael Magee as vice president, quality and compliance.

Key Points: 
  • Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction and neurological disorders, today announced the appointment of Michael Magee as vice president, quality and compliance.
  • Mr. Magee will lead and further strengthen Tris Pharma’s continued development and management of quality and compliance operations via the current Good Manufacturing Practices (cGMP) Compliance function of the organization.
  • “Michael brings a wealth of knowledge and a deep understanding of the regulatory and quality landscape, which will be instrumental in maintaining our unwavering commitment to developing therapeutics of the highest quality across ADHD, pain, addiction and neurological disorders,” said Nicholas Cappuccino, Ph.D., chief quality officer, senior vice president of quality & compliance at Tris Pharma.
  • “I look forward to collaborating with Michael to further elevate our quality assurance and regulatory compliance practices.”

Tris Pharma Appoints Franchesca Fowler to Chief Compliance Officer and Vice President, General Counsel

Retrieved on: 
Monday, January 22, 2024
Biotechnology, Neurology, Mental Health, Health, Pharmaceutical, Ketan, Patient, Pharma, JD, IP, Fordham University, Rutgers Law School, Culture, Addiction, Attention deficit hyperactivity disorder, Pain, DSM-IV codes, Bachelor of Science, Pharmaceutical industry

Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction and neurological disorders, today announced the appointment of Franchesca Fowler, JD, as chief compliance officer and vice president, general counsel.

Key Points: 
  • Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction and neurological disorders, today announced the appointment of Franchesca Fowler, JD, as chief compliance officer and vice president, general counsel.
  • Ms. Fowler will oversee all legal matters within the company, including legal compliance, IP management, litigation and more.
  • Ms. Fowler received her Bachelor of Science in Finance from Fordham University and her Juris Doctor degree from Rutgers Law School.
  • “My decision to join Tris Pharma was driven not only by its exciting pipeline and growth prospects, but also the exceptional team of dedicated professionals.

UK’s Psychiatrist-Led Diverse Diagnostics Offers Private ADHD Assessment with Free Consultations

Retrieved on: 
Friday, January 12, 2024
Patient, Attention deficit hyperactivity disorder

Diverse Diagnostics offers the following assessments:

Key Points: 
  • Diverse Diagnostics offers the following assessments:
    Recognising the growing need for accessible and reliable ADHD assessments, Diverse Diagnostics takes pride in being home to a team of qualified psychiatrists, with extensive expertise in diagnosing and managing ADHD across various age groups.
  • Key features of the private ADHD assessment service at Diverse Diagnostics include:
    Psychiatrist-Led Assessments: Led by experienced specialists in ADHD, ensuring accurate evaluations and comprehensive diagnostic procedures.
  • Free Consultations: As part of the commitment to accessible mental health care, Diverse Diagnostics offers free initial consultations to individuals seeking ADHD assessments.
  • For more information or to schedule a free consultation for a private ADHD assessment, please visit diversediagnostics.co.uk or contact [email protected] .

ABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing Fees

Retrieved on: 
Wednesday, January 3, 2024
Partnership, BioLite, Attention deficit hyperactivity disorder, Ophthalmology, CNS, MDD, ADHD, Pharmaceutical industry

The agreement between the Company and AiBtl placed a value of $460 ($10 per share) on such payment.

Key Points: 
  • The agreement between the Company and AiBtl placed a value of $460 ($10 per share) on such payment.
  • According to the terms of the agreement, AiBtl delivered 46M shares to the Company as the first milestone payment.
  • He continued, "After this licensing payment, AiBtl becomes a subsidiary of ABVC, which holds 57% of the consolidated shares of AiBtl; accordingly, AiBtl is now also considered a related party.
  • “We believe this milestone payment marks the beginning of ABVC's revenue generation through licensing deals and opens new avenues that could potentially increase ABVC's revenue.

Axsome Therapeutics Hosts Solriamfetol Virtual Investor Event with Expert Thought Leaders Today

Retrieved on: 
Thursday, December 7, 2023
Sleep medicine, Psychiatry, Attention deficit hyperactivity disorder, Obstructive sleep apnea, Eastern Time Zone, Division, Binge eating disorder, TAAR1, Psychopharmacology, BED, SHARP, Medical school, DSM-IV codes, MD, Doctor of Philosophy, Research, Therapy, University, HOPE, Associate, EDS, CNS, Narcolepsy, OSA, Webcast, Central nervous system, MDD, Patient, ADHD, Harvard Medical School, Dopamine, SWD

At the event, invited physician thought leaders will discuss current and potential future indications.

Key Points: 
  • At the event, invited physician thought leaders will discuss current and potential future indications.
  • The Axsome senior leadership team will provide an overview of clinical development plans.
  • Expert thought leaders presenting at the event include:
    Craig Chepke, MD, Medical Director of Excel Psychiatric Associates in Huntersville, N.C. and Adjunct Associate Professor of Psychiatry for Atrium Health.
  • A replay of the webcast will be available for approximately 30 days following the live event.

ABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion Market

Retrieved on: 
Tuesday, November 21, 2023
Phase, Map, Treatment, NET, Attention deficit hyperactivity disorder, European, Patent, Ophthalmology, Polygala, Norepinephrine, Norepinephrine transporter, Neurology, Pharmaceutical industry

17/120,965, for the use of PDC-1421, a Radix Polygala (Polygala tenuifolia Willd) extract, which is used in the Company's asset ABV-1505, targeting Attention Deficit/Hyperactivity Disorder (ADHD).

Key Points: 
  • 17/120,965, for the use of PDC-1421, a Radix Polygala (Polygala tenuifolia Willd) extract, which is used in the Company's asset ABV-1505, targeting Attention Deficit/Hyperactivity Disorder (ADHD).
  • "This patent grants ABVC the right to exclude others from using, offering, or selling PDC-1421 throughout the United States until 2040," said Dr. Uttam Patil, ABVC Chief Executive Officer .
  • ABVC submitted the patent application to the United States Patent and Trademark Office under "Polygala Extract for the Treatment of ADHD."
  • According to the Polaris market research report, the global ADHD treatment market was valued at $16.13 billion in 2022 and is expected to reach $32.14 billion by 2030 with a CAGR of 7.1% over the forecast period.1